查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1856989

全球精準益生菌市場：預測至2032年－按產品類型、劑型、通路、應用、最終用戶和地區分類的分析

Precision Probiotics Market Forecasts to 2032 - Global Analysis By Product Type, Form, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球精準益生菌市場預計到 2025 年將達到 18.5 億美元，到 2032 年將達到 20.8 億美元，預測期內複合年成長率為 1.7%。

精準益生菌是根據個人的健康狀況、基因組成和微生物組組成，選擇和配製的特定微生物菌株。與普通益生菌不同，精準益生菌旨在滿足特定的生理需求，從而帶來個人化的治療益處，例如改善腸道健康、調節免疫功能和支持代謝。這些菌株通常透過基因組和臨床數據進行檢驗，從而提高療效和可預測性。精準益生菌代表著機能性食品、膳食補充劑和臨床應用中，營養和微生物干預向個人化方向發展的趨勢。

根據《微生物學前沿》（2025 年）的報導，“益生菌已被證明能顯著降低抗生素相關腹瀉的發生率，有效率在 42% 到 57% 之間，具體取決於菌株和劑量。”

消費者越來越需要針對微生物的解決方案。

元基因組和人工智慧驅動的診斷技術的進步使得益生菌推薦更加精準。這些創新正在推動人們從非專利補充劑轉向標靶治療，尤其是在治療腸躁症、肥胖症和情緒障礙等慢性疾病方面。數位健康平台與微生物組科學的融合進一步加速了益生菌在健康和臨床領域的應用。隨著人們對微生物組在免疫、消化和心理健康方面作用的認知不斷提高，人們開始尋求針對自身獨特健康狀況的、具有特定菌株的配方。

複雜的科學論點會讓消費者感到困惑。

許多消費者難以區分普通益生菌和精準菌株，導致困惑和懷疑。缺乏標準化的標籤和不同人群中不一致的臨床結果進一步加劇了購買決策的複雜性。此外，嚴格的菌株驗證和監管合規要求也增加了研發時間和成本。這些障礙可能會阻礙益生菌產品進入大眾市場，尤其是在健康素養較低和監管強度較弱的地區。

拓展至心理健康與代謝健康領域

對腸腦軸和微生物對神經傳導物質影響的研究正在開闢新的治療途徑。一些公司正在研發針對焦慮、睡眠和認知功能的配方，並通常結合數位追蹤工具。同樣，針對體重管理、胰島素敏感性和血脂譜的代謝健康解決方案也不斷出現。這些創新得益於人們對非藥物干預和預防性護理日益成長的需求，尤其是在老化和健康意識增強的人群中。

科學懷疑論和不一致的結果

儘管某些菌株在對照試驗中展現出令人鼓舞的結果，但它們在實際應用中並未一致地有效。這種差異性可能會引發醫療服務提供者和監管機構的質疑，從而延緩產品核可和報銷流程。此外，大量檢驗的益生菌產品和誇大其詞的標語也會削弱消費者的信任。缺乏可靠的數據和透明的溝通，精準益生菌可能會面臨聲譽方面的挑戰，進而影響其發展。

新冠疫情的影響：

疫情提升了全球對免疫衛生的關注度，也增加了對微生物組干預的需求。針對呼吸系統韌性和全身免疫力的精準益生菌產品備受青睞。同時，遠距離診斷和居家微生物組檢測的興起，讓消費者無需前往診所即可探索個人化的腸道健康解決方案。供應鏈中斷最初影響了原料的可得性，但數位化平台和訂閱模式有助於維持用戶參與。

預計在預測期內，腰痛治療領域將成為最大的細分市場。

由於其臨床有效性和監管支持，預計在預測期內，脂質體結合蛋白（LBP）療法將佔據最大的市場佔有率。這些製劑旨在針對特定疾病進行干預，並通常有可靠的臨床試驗和FDA核准途徑作為支撐。目前，LBP正被探索用於治療潰瘍性大腸炎、泛自閉症障礙和代謝症候群等疾病。 LBP在細胞層面調節宿主-微生物組相互作用的能力使其成為下一代療法。生物技術公司和製藥公司之間的策略夥伴關係正在進一步推動創新和商業化。

預計在預測期內，消化器官系統健康細分市場將以最高的複合年成長率成長。

預計在預測期內，消化器官系統健康領域將呈現最高的成長率，這主要得益於消化器官系統疾病和生活方式相關的腸道菌叢失衡盛行率的上升。針對腹脹、腸躁症 (IBS) 和腸道菌叢失調的精準益生菌產品正日益受到消費者和臨床醫生的青睞。這些產品通常包含多種菌株的混合物，並採用標靶遞送機制以確保療效。消費者意識的提高、診斷工具的改進以及與飲食干預的結合，都為該領域帶來了積極影響。封裝和緩釋技術的創新正在提高菌株的存活率和治療效果。

比最大的地區

由於北美擁有先進的醫療基礎設施、較高的消費者健康意識和強大的研發能力，預計在預測期內將佔據最大的市場佔有率。該地區匯集了多家領先的微生物組研究機構和新興企業正在推動創新和產品核可。此外，人口老化對個人化健康和預防性醫療保健的需求日益成長，也促進了市場擴張。主要公司的策略投資和收購正在鞏固北美在該領域的領先地位。

複合年成長率最高的地區：

預計亞太地區在預測期內將呈現最高的複合年成長率，這主要得益於醫療保健投資的成長、中等收入階層的壯大以及人們對功能性營養日益成長的興趣。中國、印度和日本等國家正經歷微生物組研究和腸道健康解決方案的消費者需求激增。政府推行的預防醫學和數位健康舉措正在加速這些技術的普及應用。此外，該地區多樣化的微生物組組成也為靶向益生菌的開發提供了獨特的機會。

免費客製化服務

訂閱本報告的用戶可從以下免費自訂選項中選擇一項：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭基準化分析
    • 基於產品系列、地域覆蓋和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 引言

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 原始研究資料
    • 二手研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 市場機遇
  • 威脅
  • 產品分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 公司間的競爭

第5章 全球精準益生菌市場（依產品類型分類）

  • 治療性腰痛
  • 非處方（OTC）精準營養補充劑
  • 個人化、直接面對消費者的益生菌
  • 伴隨診斷、微生物組檢測
  • 其他產品類型

6. 全球精準益生菌市場（依形式分類）

  • 藥片
  • 藥片
  • 粉末
  • 液體
  • 軟糖
  • 其他格式

7. 全球精準益生菌市場（依分銷通路分類）

  • 網路商店
  • 藥房和藥品商店
  • 超級市場和大賣場
  • 專賣店
  • 其他分銷管道

8. 全球精準益生菌市場（依應用分類）

  • 消化器官系統健康
  • 免疫健康
  • 代謝健康
  • 心理表現
  • 體重管理
  • 皮膚健康
  • 營養最佳化
  • 其他用途

9. 全球精準益生菌市場（以最終用戶分類）

  • 醫院和診所
  • 研究機構/合約研究組織
  • 製藥和生物技術公司
  • 營養補充品和機能性食品公司
  • 動物用藥品公司
  • 其他最終用戶

第10章 全球精準益生菌市場（依地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併（M&A）
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • Nestle Health Science
  • Danone SA
  • Yakult Honsha Co., Ltd.
  • PepsiCo Inc.
  • Lifeway Foods Inc.
  • Chr. Hansen Holding A/S
  • DuPont Nutrition & Biosciences（IFF）
  • BioGaia AB
  • Probi AB
  • ADM（Archer Daniels Midland）
  • Novozymes A/S
  • Seed Health Inc.
  • ZBiotics Company
  • Amare Global
  • Pendulum Therapeutics
  • Evolve BioSystems
  • UAS Laboratories
  • Cargill Inc.
  • DSM Nutritional Products
  • Kerry Group plc
Product Code: SMRC31854

According to Stratistics MRC, the Global Precision Probiotics Market is accounted for $1.85 billion in 2025 and is expected to reach $2.08 billion by 2032 growing at a CAGR of 1.7% during the forecast period. Precision probiotics are targeted microbial strains selected and formulated based on individual health profiles, genetic makeup, and microbiome composition. Unlike general probiotics, they aim to deliver personalized therapeutic benefits such as improved gut health, immune modulation, or metabolic support by addressing specific physiological needs. These strains are often validated through genomic and clinical data, enhancing efficacy and predictability. Precision probiotics represent a shift toward customized nutrition and microbiome-based interventions in functional foods, supplements, and clinical applications.

According to Frontiers in Microbiology (2025), "Probiotics have shown a significant reduction in the incidence of antibiotic-associated diarrhea, with efficacy rates ranging from 42% to 57% depending on the strain and dosage used"

Market Dynamics:

Driver:

Consumers increasingly seek microbiome-targeted solutions

Advances in metagenomic sequencing and AI-driven diagnostics are enabling more accurate probiotic recommendations. These innovations are fostering a shift from generic supplements to targeted therapeutics, especially in chronic conditions like IBS, obesity, and mood disorders. The convergence of digital health platforms and microbiome science is further accelerating adoption across wellness and clinical segments. With increasing awareness of the microbiome's role in immunity, digestion, and mental wellness, individuals are seeking strain-specific formulations tailored to their unique health profiles.

Restraint:

Complex scientific claims may confuse consumers

Many consumers struggle to differentiate between general probiotics and precision strains, leading to confusion and skepticism. The lack of standardized labeling and inconsistent clinical outcomes across populations further complicate purchasing decisions. Additionally, the need for rigorous strain validation and regulatory compliance increases development timelines and costs. These barriers may hinder mass-market penetration, especially in regions with limited health literacy or regulatory oversight.

Opportunity:

Expansion into mental wellness and metabolic health

Research into the gut-brain axis and microbial influence on neurotransmitters is opening new therapeutic avenues. Companies are developing formulations targeting anxiety, sleep, and cognitive performance, often bundled with digital tracking tools. Similarly, metabolic health solutions are being tailored for weight management, insulin sensitivity, and lipid profiles. These innovations are supported by growing demand for non-pharmaceutical interventions and preventive care, especially among aging and health-conscious populations.

Threat:

Scientific skepticism and inconsistent results

While some strains show promise in controlled trials, replication in real-world settings remains inconsistent. This variability fuels skepticism among healthcare providers and regulators, potentially slowing product approvals and reimbursement pathways. Moreover, the influx of unverified probiotic products and exaggerated marketing claims may erode consumer trust. Without robust data and transparent communication, precision probiotics could face reputational challenges that impact growth.

Covid-19 Impact:

The pandemic heightened global awareness of immune health, prompting increased demand for microbiome-supportive interventions. Precision probiotics targeting respiratory resilience and systemic immunity saw a surge in interest. Simultaneously, the rise of remote diagnostics and at-home microbiome testing enabled consumers to explore personalized gut health solutions without clinical visits. Supply chain disruptions initially affected raw material availability, but digital platforms and subscription models helped sustain engagement.

The therapeutic LBPs segment is expected to be the largest during the forecast period

The therapeutic LBPs segment is expected to account for the largest market share during the forecast period due to their clinical relevance and regulatory traction. These formulations are designed for targeted disease intervention, often supported by robust clinical trials and FDA pathways. LBPs are being explored for conditions such as ulcerative colitis, autism spectrum disorders, and metabolic syndromes. Their ability to modulate host-microbiome interactions at a cellular level positions them as next-generation therapeutics. Strategic partnerships between biotech firms and pharmaceutical companies are further driving innovation and commercialization.

The digestive health segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the digestive health segment is predicted to witness the highest growth rate fueled by rising prevalence of gastrointestinal disorders and lifestyle-related gut imbalances. Precision probiotics targeting bloating, IBS, and dysbiosis are gaining popularity among both consumers and clinicians. These products often incorporate multi-strain blends with targeted delivery mechanisms to ensure efficacy. The segment benefits from increasing consumer awareness, improved diagnostic tools, and integration with dietary interventions. Innovations in encapsulation and time-release technologies are enhancing strain viability and therapeutic outcomes.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share attributed to advanced healthcare infrastructure, high consumer awareness, and strong R&D capabilities. The region hosts several leading microbiome research institutions and biotech startups focused on precision probiotics. Regulatory clarity from agencies like the FDA supports innovation and product approvals. Additionally, rising demand for personalized wellness and preventive care among aging populations is fueling market expansion. Strategic investments and acquisitions by major players are consolidating North America's leadership in this domain.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR supported by growing healthcare investments, expanding middle-class populations, and increasing interest in functional nutrition. Countries like China, India, and Japan are experiencing a surge in microbiome research and consumer demand for gut health solutions. Government initiatives promoting preventive care and digital health are accelerating adoption. The region's diverse microbiome profiles also offer unique opportunities for targeted probiotic development.

Key players in the market

Some of the key players in Precision Probiotics Market include Nestle Health Science, Danone S.A., Yakult Honsha Co., Ltd., PepsiCo Inc., Lifeway Foods Inc., Chr. Hansen Holding A/S, DuPont Nutrition & Biosciences (IFF), BioGaia AB, Probi AB, ADM (Archer Daniels Midland), Novozymes A/S, Seed Health Inc., ZBiotics Company, Amare Global, Pendulum Therapeutics, Evolve BioSystems, UAS Laboratories, Cargill Inc., DSM Nutritional Products, and Kerry Group plc.

Key Developments:

In September 2025, Lifeway Foods Inc. Signed Cooperation Agreement with Danone North America for board refreshment, includes governance changes and litigation stay to enhance shareholder value.

In August 2025, Chr. Hansen Holding A/S Launched 2025 Strategy to focus on microbial platforms and fermented plant bases, aims to become a differentiated bioscience leader in food and health.

In June 2025, Nestle Health Science Launched BOOST(R) Advanced Nutritional Shake for adults on GLP-1 weight loss journeys. Supports nutritional needs with high protein and fiber, tailored for metabolic health.

Product Types Covered:

  • Therapeutic LBPs
  • Over-the-Counter (OTC) Precision Supplements
  • Personalized, DTC-Formulated Probiotics
  • Companion Diagnostics & Microbiome Tests
  • Other Product Types

Forms Covered:

  • Capsules
  • Tablets
  • Powders
  • Liquids
  • Gummies
  • Other Forms

Distribution Channels Covered:

  • Online Stores
  • Pharmacies & Drug Stores
  • Supermarkets &Hypermarkets
  • Specialty Stores
  • Other Distribution Channels

Applications Covered:

  • Digestive Health
  • Immune Health
  • Metabolic Health
  • Mental Performance
  • Weight Management
  • Skin Health
  • Nutrition Optimization
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Research Institutes & CROs
  • Pharmaceutical & Biotech Companies
  • Nutraceutical & Functional Food Companies
  • Animal Health Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Precision Probiotics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Therapeutic LBPs
  • 5.3 Over-the-Counter (OTC) Precision Supplements
  • 5.4 Personalized, DTC-Formulated Probiotics
  • 5.5 Companion Diagnostics & Microbiome Tests
  • 5.6 Other Product Types

6 Global Precision Probiotics Market, By Form

  • 6.1 Introduction
  • 6.2 Capsules
  • 6.3 Tablets
  • 6.4 Powders
  • 6.5 Liquids
  • 6.6 Gummies
  • 6.7 Other Forms

7 Global Precision Probiotics Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Online Stores
  • 7.3 Pharmacies & Drug Stores
  • 7.4 Supermarkets &Hypermarkets
  • 7.5 Specialty Stores
  • 7.6 Other Distribution Channels

8 Global Precision Probiotics Market, By Application

  • 8.1 Introduction
  • 8.2 Digestive Health
  • 8.3 Immune Health
  • 8.4 Metabolic Health
  • 8.5 Mental Performance
  • 8.6 Weight Management
  • 8.7 Skin Health
  • 8.8 Nutrition Optimization
  • 8.9 Other Applications

9 Global Precision Probiotics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Research Institutes & CROs
  • 9.4 Pharmaceutical & Biotech Companies
  • 9.5 Nutraceutical & Functional Food Companies
  • 9.6 Animal Health Companies
  • 9.7 Other End Users

10 Global Precision Probiotics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Nestle Health Science
  • 12.2 Danone S.A.
  • 12.3 Yakult Honsha Co., Ltd.
  • 12.4 PepsiCo Inc.
  • 12.5 Lifeway Foods Inc.
  • 12.6 Chr. Hansen Holding A/S
  • 12.7 DuPont Nutrition & Biosciences (IFF)
  • 12.8 BioGaia AB
  • 12.9 Probi AB
  • 12.10 ADM (Archer Daniels Midland)
  • 12.11 Novozymes A/S
  • 12.12 Seed Health Inc.
  • 12.13 ZBiotics Company
  • 12.14 Amare Global
  • 12.15 Pendulum Therapeutics
  • 12.16 Evolve BioSystems
  • 12.17 UAS Laboratories
  • 12.18 Cargill Inc.
  • 12.19 DSM Nutritional Products
  • 12.20 Kerry Group plc

List of Tables

  • Table 1 Global Precision Probiotics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Precision Probiotics Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Precision Probiotics Market Outlook, By Therapeutic LBPs (2024-2032) ($MN)
  • Table 4 Global Precision Probiotics Market Outlook, By Over-the-Counter (OTC) Precision Supplements (2024-2032) ($MN)
  • Table 5 Global Precision Probiotics Market Outlook, By Personalized, DTC-Formulated Probiotics (2024-2032) ($MN)
  • Table 6 Global Precision Probiotics Market Outlook, By Companion Diagnostics & Microbiome Tests (2024-2032) ($MN)
  • Table 7 Global Precision Probiotics Market Outlook, By Other Product Types (2024-2032) ($MN)
  • Table 8 Global Precision Probiotics Market Outlook, By Form (2024-2032) ($MN)
  • Table 9 Global Precision Probiotics Market Outlook, By Capsules (2024-2032) ($MN)
  • Table 10 Global Precision Probiotics Market Outlook, By Tablets (2024-2032) ($MN)
  • Table 11 Global Precision Probiotics Market Outlook, By Powders (2024-2032) ($MN)
  • Table 12 Global Precision Probiotics Market Outlook, By Liquids (2024-2032) ($MN)
  • Table 13 Global Precision Probiotics Market Outlook, By Gummies (2024-2032) ($MN)
  • Table 14 Global Precision Probiotics Market Outlook, By Other Forms (2024-2032) ($MN)
  • Table 15 Global Precision Probiotics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 16 Global Precision Probiotics Market Outlook, By Online Stores (2024-2032) ($MN)
  • Table 17 Global Precision Probiotics Market Outlook, By Pharmacies & Drug Stores (2024-2032) ($MN)
  • Table 18 Global Precision Probiotics Market Outlook, By Supermarkets &Hypermarkets (2024-2032) ($MN)
  • Table 19 Global Precision Probiotics Market Outlook, By Specialty Stores (2024-2032) ($MN)
  • Table 20 Global Precision Probiotics Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
  • Table 21 Global Precision Probiotics Market Outlook, By Application (2024-2032) ($MN)
  • Table 22 Global Precision Probiotics Market Outlook, By Digestive Health (2024-2032) ($MN)
  • Table 23 Global Precision Probiotics Market Outlook, By Immune Health (2024-2032) ($MN)
  • Table 24 Global Precision Probiotics Market Outlook, By Metabolic Health (2024-2032) ($MN)
  • Table 25 Global Precision Probiotics Market Outlook, By Mental Performance (2024-2032) ($MN)
  • Table 26 Global Precision Probiotics Market Outlook, By Weight Management (2024-2032) ($MN)
  • Table 27 Global Precision Probiotics Market Outlook, By Skin Health (2024-2032) ($MN)
  • Table 28 Global Precision Probiotics Market Outlook, By Nutrition Optimization (2024-2032) ($MN)
  • Table 29 Global Precision Probiotics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 30 Global Precision Probiotics Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Precision Probiotics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 32 Global Precision Probiotics Market Outlook, By Research Institutes & CROs (2024-2032) ($MN)
  • Table 33 Global Precision Probiotics Market Outlook, By Pharmaceutical & Biotech Companies (2024-2032) ($MN)
  • Table 34 Global Precision Probiotics Market Outlook, By Nutraceutical & Functional Food Companies (2024-2032) ($MN)
  • Table 35 Global Precision Probiotics Market Outlook, By Animal Health Companies (2024-2032) ($MN)
  • Table 36 Global Precision Probiotics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.